ImmunityBio (IBRX) Receivables - Other (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Receivables - Other data on file, last reported at $3000.0 in Q1 2026.

• Receivables - Other for Q1 2026 came in at $3000.0, down 99.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $3000.0 (down 99.29% YoY), and the FY2025 annual result was $46000.0, down 77.0% from the prior year.
• Receivables - Other fell to $3000.0 in Q1 2026 per IBRX's latest filing, from $46000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $5.0 million in Q2 2022 and troughed at $3000.0 in Q1 2026.
• A 5-year average of $1.6 million and a median of $1.5 million in 2022 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2026: Receivables - Other surged 289.3% in 2022, then tumbled 99.29% in 2026.
• A 5-year view of Receivables - Other shows it stood at $1.9 million in 2022, then rose by 6.83% to $2.0 million in 2023, then plunged by 90.09% to $200000.0 in 2024, then tumbled by 77.0% to $46000.0 in 2025, then tumbled by 93.48% to $3000.0 in 2026.
• Business Quant data shows IBRX's Receivables - Other at $3000.0 in Q1 2026, $46000.0 in Q4 2025, and $1.7 million in Q3 2025.